# 1. Financial Performance ## A. Key Figures * **Revenue from Operations:** **₹52.8 Cr** Standalone (+1%) * **Collection Growth:** **7%** Clinic Business * **Profitability (PAT):** **(₹14.2 Cr)** Standalone Loss · ₹6.4 Cr Q1 FY25 Profit (incl. ₹15.8 Cr one-time gain) * **Operating Margins:** **26%–27%** Clinic-level EBITDA ## B. Revenue and Collections * **Steady Top-line Performance:** Revenue from operations remained largely flat year-on-year, though the core clinic business demonstrated healthier momentum in collections. ## C. Margins and Profitability * **Earnings Volatility:** The shift from profit to a significant loss is primarily attributed to the absence of a **₹15.8 Cr** one-time gain (impairment reversals/IP sales) that inflated the prior year's results. * **Operating Leverage Challenges:** Robust clinic-level margins are currently being diluted by heavy corporate overheads and aggressive marketing spend aimed at customer acquisition. ## D. Cost Structure Analysis * **Rising Personnel Costs:** Employee benefit expenses increased to **₹16.24 Cr** (reported as 16.24 lakhs in error in notes), reflecting pressures from clinic expansion, wage inflation, or productivity-linked incentives. --- # 2. Service & Product Performance ## A. Key Figures * **Collection Growth:** **6%** Services segment · **11%** Clinic product business * **Category Growth:** **20%** Hair Care · **13%** Brightening & Pigmentation * **Revenue Mix:** **85%** Services · **15%** Products * **Innovation Contribution:** **5%** New Product Development · **6%** New Service Development ## B. Service & Product Category Trends * **Service Momentum:** Total service collections saw single-digit growth, anchored by double-digit outperformance in the Hair Care and Pigmentation verticals. * **Product Portfolio Strength:** The product business outpaced services in growth rate, fueled primarily by the Bath and Body, Nutraceuticals, and Sun Care categories. * **Revenue Composition:** The business model remains heavily service-centric, with services generating the vast majority of total revenue. ## C. Innovation & Infrastructure * **R&D as a Growth Lever:** New service and product launches are critical performance drivers, collectively contributing **11%** to total India clinic collections. * **Technology Capex:** Significant investment in **31 new dermatology machines** during Q1 aims to upgrade capabilities in high-growth areas like Anti-Aging and Laser Hair Reduction. --- # 3. Clinic & Operational Metrics ## A. Key Figures * **Net Promoter Score (NPS):** **90** Q1 FY '26 * **Kaya Smiles Contribution:** **>90%** of clinic collections * New Customer Growth: +6% increase in performance marketing count, reversing prior negative trend * **Clinic Expansion:** **2** clinics launched Q1 · **1** clinic launched Q2 · **5** clinics signed/upcoming ## B. Footprint and Expansion * **Strategic Scaling:** Aggressive footprint expansion focused on high-potential hubs like Bangalore and Noida to drive top-line growth. * **Profitability Lever:** New clinic launches are designed to leverage existing head office overheads, aiming for improved consolidated margins. * **Network Velocity:** Management expects to reach a total of **eight** new clinics by September or October, signaling a rapid acceleration in physical presence. ## C. Infrastructure Utilization * **Capacity Optimization:** Strategy centers on closing the "utilization gap" within existing infrastructure, particularly targeting weekday volume to maximize fixed-cost absorption. * **Operating Leverage:** Increased throughput is expected to flow directly to the bottom line as current staffing and facilities possess significant available capacity. * **Financial De-leveraging:** Profitability roadmap includes reducing interest burdens via equity dilution alongside infrastructure-led revenue growth. ## D. Marketing and Retention * **Digital Transformation:** Implementation of WhatsApp and web chatbots to automate the customer journey and streamline appointment scheduling. * **Acquisition Pivot:** Marketing spend is being redirected toward performance-based customer acquisition to reverse previous negative growth trends. * **Loyalty Ecosystem:** High reliance on the Kaya Smiles program, with a focus on experiential marketing and tiered benefits for **Platinum and Gold Elite** members to secure recurring revenue. --- # 4. Strategic Investments & Partnerships ## A. Key Figures * **Preferential Allotment:** **₹75 Cr** Capital infusion via strategic route * **Original Rights Issue Proposal:** **₹300 Cr** Initial fundraising target * **Completion Timeline:** **August 2025** Expected closure of preferential allotment ## B. Preferential Allotment Details * **Strategic Pivot:** Management shifted from a large-scale rights issue to a smaller preferential allotment to prioritize speed and simplicity in supporting immediate growth. * **High-Pedigree Partnership:** The allotment introduces **Axana Estates (Mithun Sacheti)** as a strategic investor, leveraging his expertise in scaling major digital-first retail platforms. [5, 7] * **Governance Status:** Despite the strategic nature of the investment, the board has deferred any decision regarding granting the new investor a **board seat**. ## C. Future Equity Plans * **Phased Fundraising:** A rights issue remains a viable secondary option for existing shareholders, though formalization is contingent upon the successful execution of the current allotment. * **Capital Roadmap:** Post-August 2025, the board will evaluate the timing and necessity of further equity dilution to fund long-term strategic initiatives. --- # 5. Risks & Consumer Trends ## A. Key Figures * **Consumable Costs:** **₹8.28 Lakhs** Standalone business ## B. Wage and Consumable Inflation * **Labor Cost Drivers:** Employee benefit expenses are trending upward, pressured by annual wage increments, productivity-linked incentives, and headcount scaling for new clinic expansions. * **Shift in Service Mix:** Rising consumable expenditure is directly linked to a strategic pivot toward high-growth categories—specifically **Body Contouring, Acne Scars, and Anti-Aging**—which carry higher supply requirements. --- # 6. Guidance & Outlook ## A. Key Figures * **Revenue Growth:** **7% to 8%** Q1 Actuals · **13% to 14%** 5-Year Industry Projection ## B. Revenue Acceleration Targets * **Growth Catch-up Strategy:** Management aims to bridge the gap between current single-digit performance and double-digit industry benchmarks through **increased marketing investment**. * **Operational Efficiency:** Acceleration plans rely heavily on achieving better utilization of existing infrastructure to drive top-line momentum.